<DOC>
	<DOCNO>NCT00716170</DOCNO>
	<brief_summary>In order investigate mechanism underlie hyperglucagonemia characterize patient type 2 diabetes mellitus ( T2DM ) wish test follow hypothesis : Do pancreatic alpha-cells exhibit inappropriate glucagon response substance release small intestine ( GIP , GLP-2 GLP-2 ) patient T2DM ?</brief_summary>
	<brief_title>GIP , GLP-1 GLP-2 Type 2 Diabetic Hyperglucagonemia</brief_title>
	<detailed_description>Patients T2DM able suppress secretion glucagon meal oral ingestion glucose . Patients actually respond pathological high plasmaglucagon concentration stimuli . Previous study show postprandial hyperglucagonemia result increase hepatic glucose production therefore contribute significantly hyperglycemia characterize patient . Recently show patient T2DM exhibit normal suppression glucagon secretion follow adjustable intravenous ( iv ) glucose challenge mimic glucose excursion follow 50-g oral glucose tolerance test ( OGTT ) latter result lack glucagon suppression . Why difference ? A possible explanation could oral administration stimulate intestinal factor result differentially glucagon response two similar glucose excursion . We wish establish whether GIP , GLP-1 and/or GLP-2 responsible inappropriate glucagon suppression follow OGTT meal patient T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Caucasians diet and/or tablet treat T2DM least 3 month duration ( diagnose accord criterias World Health Organization ( WHO ) ) Normal Hemoglobin Prior Informed Consent Liver disease ( ALAT/ASAT &gt; 2 x upper normal value ) Diabetic nephropathy ( secreatinin &gt; 130 um and/or albuminuria Treatment drug discontinue 12 hour</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Insulin</keyword>
	<keyword>Incretin hormone</keyword>
	<keyword>Glucose-dependent insulinotropic polypeptide</keyword>
	<keyword>Glucagon-like peptide-1</keyword>
	<keyword>Glucagon-like peptide-2</keyword>
</DOC>